Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cosibelimab + Lenalidomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cosibelimab | Unloxcyt | CK-301|CK 301|TG-1501|TG1501|TG 1501|cosibelimab-ipdl | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 141 | Unloxcyt (cosibelimab) is a human monoclonal antibody against PD-L1 (CD274), which may block immune checkpoint, and lead to anti-tumor immune response (PMID: 37848259). Unloxcyt (cosibelimab) is FDA approved for use in adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation (FDA.gov). |
| Lenalidomide | Revlimid | IMiD-1 | Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07926893 | Phase I | Cosibelimab + Lenalidomide | Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sezary Syndrome | Not yet recruiting | USA | 0 |